Latest Amarin Corporation Plc (AMRN) Headlines
Post# of 109
Posted On: 03/12/2014 5:48:54 PM
Latest Amarin Corporation Plc (AMRN) Headlines
3 Stocks Under $10 Triggering Breakouts
at The Street - Wed Mar 12, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
If You Can't Make Your Drug a Blockbuster, Sue Your Competitor
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 04, 4:34PM CST
Amarin 's lawyers sure are keeping busy. The company is appealing the Food and Drug Administration's decision to rescind the Special Protocol Assessment, or SPA, for its fish oil pill Vascepa. The SPA would allow the biotech to gain expanded...
Can Amarin Corporation PLC Stop Burning Cash?
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 28, 1:16PM CST
A 20% quarter-over-quarter growth may sound like solid growth, but not when it only gets you to $10.1 million in net sales. It's hard to be impressed by the launch of Amarin 's fish oil Vascepa. To put it in perspective, the biotech had $22 million...
Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations
GlobeNewswire - Thu Feb 27, 3:14PM CST
Amarin Corporation plc (Nasdaq:AMRN), a late stage biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter and year ended December 31, 2013, and provided an update on company operations.
Two Years Less Exclusivity Is the Least of Amarin's Issues
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 25, 8:30AM CST
The Food and Drug Administration usually takes about a month to make a decision about how long a drug will have exclusivity. Unless you're Amarin . Then it takes about 19 months. And the answer isn't exactly what investors were hoping for. On...
Monday’s Winners and Losers: Celsion Corporation, Celladon Corp, and Amarin Corporation plc
David Williamson, The Motley Fool - Motley Fool - Mon Feb 24, 8:26PM CST
In this video, Motley Fool health-care analyst David Williamson takes a look at Celsion Corp and Celladon (NASDAQ: CLDN ) as today's two winners in the health-care space, and he also discusses some bad news for Amarin . Celsion has...
Amarin's Vascepa Gets 3-Year Exclusivity - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 4:20PM CST
Amarin announced that Vascepa was given 3 years of marketing exclusivity by FDA in connection with the MARINE indication.
Amarin Loses Bid for Vascepa 5-Year Market Exclusivity
at The Street - Mon Feb 24, 6:59AM CST
Sales of the prescription fish-oil are so low that generic drug makers may simply pass the product by.
Amarin to Report Fourth Quarter and Year-End 2013 Results and Host Conference Call on February 27, 2014
GlobeNewswire - Mon Feb 24, 5:00AM CST
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's fourth quarter and year-end 2013 financial results and provide an operational update on Thursday, February 27, 2014, at 4:30 p.m. ET. The conference call will follow the anticipated release of the company's fourth quarter and year-end 2013 financial results earlier that day.
Amarin Given 3-Year Exclusivity for Vascepa
Eric Volkman, The Motley Fool - Motley Fool - Fri Feb 21, 9:05PM CST
Amarin has received an important approval from the Food and Drug Administration, but the company is not necessarily happy about it. The FDA awarded the firm three years of marketing exclusivity for Vascepa capsules. That approval expires in July...
Amarin Announces FDA Award of Three-Year Exclusivity for Vascepa(R) (icosapent ethyl) Capsules
GlobeNewswire - Fri Feb 21, 3:01PM CST
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Food and Drug Administration (FDA) has awarded three years of marketing exclusivity to Vascepa (icosapent ethyl) capsules in connection with the July 26, 2012 approval of Vascepa pursuant to the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. Such exclusivity extends through July 25, 2015 and is expected to be supplemented by a 30-month stay under the Hatch-Waxman Amendments that would be triggered after patent infringement litigation initiated by Amarin following valid notice to Amarin of the acceptance of an application to the FDA seeking approval of a generic version of Vascepa. FDA marketing exclusivity is separate from, and in addition to, patent protection, trade secrets and manufacturing barriers to entry which also help protect Vascepa against generic competition.
Biotech Stocks to Trade for Breakouts: Amarin
at The Street - Thu Feb 20, 7:27AM CST
Amarin's recent moves are starting to push shares within range of triggering a big breakout trade.
3 Biotech Stocks on the Verge of Breakouts: Amarin, Star Scientific, Columbia Labs
at The Street - Thu Feb 20, 5:00AM CST
These three biotech stocks trading for under $10 are within range of triggering breakout trades.
3 Biotech Stocks to Avoid: Amarin, Dendreon, and Prosensa
Leo Sun, The Motley Fool - Motley Fool - Mon Feb 17, 2:37PM CST
In the stock market, everyone loves a great turnaround story. In the biotech sector, where companies can rally or plunge by the double-digits on an FDA approval or rejection, bottom-fishing investors love to search for broken stocks with overlooked...
Amarin Corporation Plc's Rocky Road
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 14, 2:20PM CST
Amarin has been a roller coaster of a stock since the launch of its fish oil drug Vascepa. The drug competes with GlaxoSmithKline 's fish oil Lovaza, but while Glaxo's drug is often used off label in patients with moderately high triglyceride...
Demand Outlook for T&D Electrical Equipment Market in India - Transformer, Switchgear & Energy Meters
PR Newswire - Fri Feb 14, 11:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/77j8t4/demand_outlook) has announced the addition of the "Demand Outlook for T&D Electrical Equipment Market in India - Transformer, Switchgear & Energy Meters" report to their offering.
Amarin to Present at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 06, 5:30AM CST
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the 2014 Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York City on Thursday, February 13, 2014, at 11:10 a.m. ET.
3 Biotech Stocks Under $10 Making Big Moves
at The Street - Wed Feb 05, 8:03AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Amarin Corporation plc names Aaron Berg to new role of SVP of Marketing and Sales
M2 - Wed Feb 05, 5:33AM CST
Biopharmaceutical company Amarin Corporation plc (NasdaqGM:AMRN) reported on Tuesday the promotion of Aaron Berg to senior vice president of its Marketing and Sales.
Zimplats Revenue Falls 13 Percent
All Africa Global Media - Tue Feb 04, 5:24AM CST
Zimbabwe Platinum Mines said revenue for the quarter ended December 31 fell 13 percent from the quarter ended September due to lower sales and depressed platinum prices.Revenue for the period was US$125,9 million, down from US$145,5 million in the previous quarter. Compared with the quarter ended December 2012, Zimplat's revenue is up 52 percent.
3 Stocks Under $10 Triggering Breakouts
at The Street - Wed Mar 12, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
If You Can't Make Your Drug a Blockbuster, Sue Your Competitor
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 04, 4:34PM CST
Amarin 's lawyers sure are keeping busy. The company is appealing the Food and Drug Administration's decision to rescind the Special Protocol Assessment, or SPA, for its fish oil pill Vascepa. The SPA would allow the biotech to gain expanded...
Can Amarin Corporation PLC Stop Burning Cash?
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 28, 1:16PM CST
A 20% quarter-over-quarter growth may sound like solid growth, but not when it only gets you to $10.1 million in net sales. It's hard to be impressed by the launch of Amarin 's fish oil Vascepa. To put it in perspective, the biotech had $22 million...
Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations
GlobeNewswire - Thu Feb 27, 3:14PM CST
Amarin Corporation plc (Nasdaq:AMRN), a late stage biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter and year ended December 31, 2013, and provided an update on company operations.
Two Years Less Exclusivity Is the Least of Amarin's Issues
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 25, 8:30AM CST
The Food and Drug Administration usually takes about a month to make a decision about how long a drug will have exclusivity. Unless you're Amarin . Then it takes about 19 months. And the answer isn't exactly what investors were hoping for. On...
Monday’s Winners and Losers: Celsion Corporation, Celladon Corp, and Amarin Corporation plc
David Williamson, The Motley Fool - Motley Fool - Mon Feb 24, 8:26PM CST
In this video, Motley Fool health-care analyst David Williamson takes a look at Celsion Corp and Celladon (NASDAQ: CLDN ) as today's two winners in the health-care space, and he also discusses some bad news for Amarin . Celsion has...
Amarin's Vascepa Gets 3-Year Exclusivity - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 4:20PM CST
Amarin announced that Vascepa was given 3 years of marketing exclusivity by FDA in connection with the MARINE indication.
Amarin Loses Bid for Vascepa 5-Year Market Exclusivity
at The Street - Mon Feb 24, 6:59AM CST
Sales of the prescription fish-oil are so low that generic drug makers may simply pass the product by.
Amarin to Report Fourth Quarter and Year-End 2013 Results and Host Conference Call on February 27, 2014
GlobeNewswire - Mon Feb 24, 5:00AM CST
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's fourth quarter and year-end 2013 financial results and provide an operational update on Thursday, February 27, 2014, at 4:30 p.m. ET. The conference call will follow the anticipated release of the company's fourth quarter and year-end 2013 financial results earlier that day.
Amarin Given 3-Year Exclusivity for Vascepa
Eric Volkman, The Motley Fool - Motley Fool - Fri Feb 21, 9:05PM CST
Amarin has received an important approval from the Food and Drug Administration, but the company is not necessarily happy about it. The FDA awarded the firm three years of marketing exclusivity for Vascepa capsules. That approval expires in July...
Amarin Announces FDA Award of Three-Year Exclusivity for Vascepa(R) (icosapent ethyl) Capsules
GlobeNewswire - Fri Feb 21, 3:01PM CST
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the U.S. Food and Drug Administration (FDA) has awarded three years of marketing exclusivity to Vascepa (icosapent ethyl) capsules in connection with the July 26, 2012 approval of Vascepa pursuant to the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. Such exclusivity extends through July 25, 2015 and is expected to be supplemented by a 30-month stay under the Hatch-Waxman Amendments that would be triggered after patent infringement litigation initiated by Amarin following valid notice to Amarin of the acceptance of an application to the FDA seeking approval of a generic version of Vascepa. FDA marketing exclusivity is separate from, and in addition to, patent protection, trade secrets and manufacturing barriers to entry which also help protect Vascepa against generic competition.
Biotech Stocks to Trade for Breakouts: Amarin
at The Street - Thu Feb 20, 7:27AM CST
Amarin's recent moves are starting to push shares within range of triggering a big breakout trade.
3 Biotech Stocks on the Verge of Breakouts: Amarin, Star Scientific, Columbia Labs
at The Street - Thu Feb 20, 5:00AM CST
These three biotech stocks trading for under $10 are within range of triggering breakout trades.
3 Biotech Stocks to Avoid: Amarin, Dendreon, and Prosensa
Leo Sun, The Motley Fool - Motley Fool - Mon Feb 17, 2:37PM CST
In the stock market, everyone loves a great turnaround story. In the biotech sector, where companies can rally or plunge by the double-digits on an FDA approval or rejection, bottom-fishing investors love to search for broken stocks with overlooked...
Amarin Corporation Plc's Rocky Road
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 14, 2:20PM CST
Amarin has been a roller coaster of a stock since the launch of its fish oil drug Vascepa. The drug competes with GlaxoSmithKline 's fish oil Lovaza, but while Glaxo's drug is often used off label in patients with moderately high triglyceride...
Demand Outlook for T&D Electrical Equipment Market in India - Transformer, Switchgear & Energy Meters
PR Newswire - Fri Feb 14, 11:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/77j8t4/demand_outlook) has announced the addition of the "Demand Outlook for T&D Electrical Equipment Market in India - Transformer, Switchgear & Energy Meters" report to their offering.
Amarin to Present at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 06, 5:30AM CST
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the 2014 Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York City on Thursday, February 13, 2014, at 11:10 a.m. ET.
3 Biotech Stocks Under $10 Making Big Moves
at The Street - Wed Feb 05, 8:03AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Amarin Corporation plc names Aaron Berg to new role of SVP of Marketing and Sales
M2 - Wed Feb 05, 5:33AM CST
Biopharmaceutical company Amarin Corporation plc (NasdaqGM:AMRN) reported on Tuesday the promotion of Aaron Berg to senior vice president of its Marketing and Sales.
Zimplats Revenue Falls 13 Percent
All Africa Global Media - Tue Feb 04, 5:24AM CST
Zimbabwe Platinum Mines said revenue for the quarter ended December 31 fell 13 percent from the quarter ended September due to lower sales and depressed platinum prices.Revenue for the period was US$125,9 million, down from US$145,5 million in the previous quarter. Compared with the quarter ended December 2012, Zimplat's revenue is up 52 percent.
(0)
(0)Amarin Corporation Plc (AMRN) Stock Research Links
Scroll down for more posts ▼